Telix agrees to buy ITM Isotope Technologies Munich for USD 1.65 billion upfront, plus up to USD 700 million milestones

Telix Pharmaceuticals agreed to acquire ITM Isotope Technologies Munich for USD 1.65 billion on a cash-free, debt-free basis. Consideration includes USD 1.25 billion in 105,800,000 Telix shares priced at USD 11.84, USD 302 million net debt assumed. Deal also includes up to USD 700 million in contingent payments tied to ITM-11 regulatory approvals and sales milestones. ITM supplies therapeutic radioisotopes, including commercial-grade lutetium-177, strengthening Telix’s isotope supply and manufacturing integration. ITM-11 for GEP-NETs has completed Phase 3, supporting a potential near-term entry into targeted radionuclide therapy markets. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via (Ref. ID: 202609202055PRIMZONEFULLFEED9830217) on September 21, 2026, and is solely responsible for the information contained therein. (C) Copyright.